Heleen M. Den Hertog
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Heleen M. Den Hertog has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Ale Algra
Department of Neurology, Utrecht Stroke Center, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands
3 shared publications- Diederik W. J. Dippel
Department of Neurology, Erasmus MC, Rotterdam, Netherlands
3 shared publications D. W. J. Dippel
Department of Neurology, Erasmus MC University Medical Center, Rotterdam
2 shared publicationsDiederik W. J. Dippel
Department of Neurology, Erasmus MC University Medical Center, Rotterdam, the Netherlands
2 shared publicationsH Bart Van Der Worp
2 shared publications- Hendrik Bernardus van der Worp
Department of Neurology and Neurosurgery, Brain Center, University Medical Center Utrecht, the Netherlands (H.B.v.d.W.).
2 shared publications
Latest Publications
- 15 March 2013
- Published by SAGE Publications in International Journal of Stroke
- Vol. 10 (1) , 105-109
Safety and FeasibiLity of Metformin in Patients with Impaired Glucose Tolerance and a Recent TIA or Minor Ischemic Stroke (LIMIT) Trial – A Multicenter, Randomized, Open-Label Phase II Trial
Background and purpose: We aimed to assess the safety, feasibility, and effects on glucose metabolism of treatment with metformin in patients with TIA or minor ischemic stroke and impaired glucose tolerance. Methods: We performed a multicenter, randomized, controlled, open-label phase II trial with blinded outcome assessment. Patients with TIA or minor ischemic stroke in the previous six months and impaired glucose tolerance (2-hour post-load glucose levels of 7.8–11.0 mmol/l) were randomized to metformin, in a daily dose of 2 g, or no metformin, for three months. Primary outcome measures were safety and feasibility of metformin, and the adjusted difference in 2-hour post-load glucose levels at three months. This trial is registered as an International Standard Randomized Controlled Trial Number 54960762. Results: Forty patients were enrolled; 19 patients were randomly assigned metformin. Nine patients in the metformin group had side effects, mostly gastrointestinal, leading to permanent discontinuation in four patients after 3–10 weeks. Treatment with metformin was associated with a significant reduction in 2-hour post-load glucose levels of 0·97 mmol/l (95% CI 0·11–1·83) in the on-treatment analysis, but not in the intention-to-treat analysis (0·71 mmol/l; 95% CI −0·36 to 1·78). Conclusions: Treatment with metformin in patients with TIA or minor ischemic stroke and impaired glucose tolerance is safe, but leads to minor side effects. If tolerated, it may lead to a significant reduction in post-load glucose levels. This suggests that the role of metformin as potential therapeutic agent for secondary stroke prevention should be further explored.
- 15 March 2013
- Published by SAGE Publications in International Journal of Stroke
- Vol. 10 (1) , 105-109
Safety and FeasibiLity of Metformin in Patients with Impaired Glucose Tolerance and a Recent TIA or Minor Ischemic Stroke (LIMIT) Trial – A Multicenter, Randomized, Open-Label Phase II Trial
Background and purpose: We aimed to assess the safety, feasibility, and effects on glucose metabolism of treatment with metformin in patients with TIA or minor ischemic stroke and impaired glucose tolerance. Methods: We performed a multicenter, randomized, controlled, open-label phase II trial with blinded outcome assessment. Patients with TIA or minor ischemic stroke in the previous six months and impaired glucose tolerance (2-hour post-load glucose levels of 7.8–11.0 mmol/l) were randomized to metformin, in a daily dose of 2 g, or no metformin, for three months. Primary outcome measures were safety and feasibility of metformin, and the adjusted difference in 2-hour post-load glucose levels at three months. This trial is registered as an International Standard Randomized Controlled Trial Number 54960762. Results: Forty patients were enrolled; 19 patients were randomly assigned metformin. Nine patients in the metformin group had side effects, mostly gastrointestinal, leading to permanent discontinuation in four patients after 3–10 weeks. Treatment with metformin was associated with a significant reduction in 2-hour post-load glucose levels of 0·97 mmol/l (95% CI 0·11–1·83) in the on-treatment analysis, but not in the intention-to-treat analysis (0·71 mmol/l; 95% CI −0·36 to 1·78). Conclusions: Treatment with metformin in patients with TIA or minor ischemic stroke and impaired glucose tolerance is safe, but leads to minor side effects. If tolerated, it may lead to a significant reduction in post-load glucose levels. This suggests that the role of metformin as potential therapeutic agent for secondary stroke prevention should be further explored.
- 1 November 2012
- Published by Wolters Kluwer Health in Stroke
- Vol. 43 (11)
Preventive Antibiotics in Acute Stroke
- 1 November 2012
- Published by Wolters Kluwer Health in Stroke
- Vol. 43 (11)
Preventive Antibiotics in Acute Stroke
- 8 June 2011
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 125 (4) , 265-271
Effects of high-dose paracetamol on blood pressure in acute stroke
Early administration of paracetamol may improve outcome of patients with acute stroke and a baseline body temperature of 37°C or above by lowering body temperature and preventing fever. Besides its antipyretic effects, paracetamol may affect blood pressure through cyclooxygenase-2 inhibition. We therefore aimed to assess the effect of high-dose paracetamol on blood pressure in patients with acute stroke. We analyzed data of 540 patients admitted within 24 h of stroke onset who were randomized to treatment with either paracetamol (6 g daily) or placebo. Blood pressures were measured at 12, 24, and 48 h from the start of treatment. Changes in blood pressure from baseline in the two treatment groups and corresponding 95% confidence intervals (CI) were calculated with linear regression analysis. Adjustments for potential confounders were made with a multiple linear regression model. Treatment with high-dose paracetamol was associated with a significant reduction in systolic blood pressure of 4.5 mm Hg (95% CI 0.6-8.5) at 12 h from the start of treatment. This effect was no longer present after 24 and 48 h. High-dose paracetamol reduces not only body temperature but also systolic blood pressure in the first 12 h after start of treatment. Both effects may improve functional outcome after stroke, but this needs further study.
- 8 June 2011
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 125 (4) , 265-271
Effects of high-dose paracetamol on blood pressure in acute stroke
Early administration of paracetamol may improve outcome of patients with acute stroke and a baseline body temperature of 37°C or above by lowering body temperature and preventing fever. Besides its antipyretic effects, paracetamol may affect blood pressure through cyclooxygenase-2 inhibition. We therefore aimed to assess the effect of high-dose paracetamol on blood pressure in patients with acute stroke. We analyzed data of 540 patients admitted within 24 h of stroke onset who were randomized to treatment with either paracetamol (6 g daily) or placebo. Blood pressures were measured at 12, 24, and 48 h from the start of treatment. Changes in blood pressure from baseline in the two treatment groups and corresponding 95% confidence intervals (CI) were calculated with linear regression analysis. Adjustments for potential confounders were made with a multiple linear regression model. Treatment with high-dose paracetamol was associated with a significant reduction in systolic blood pressure of 4.5 mm Hg (95% CI 0.6-8.5) at 12 h from the start of treatment. This effect was no longer present after 24 and 48 h. High-dose paracetamol reduces not only body temperature but also systolic blood pressure in the first 12 h after start of treatment. Both effects may improve functional outcome after stroke, but this needs further study.
- Open Access
- 30 September 2010
- Published by Springer Nature in Journal of Neurology
- Vol. 258 (2) , 302-307
An early rise in body temperature is related to unfavorable outcome after stroke: data from the PAIS study
Subfebrile temperature or fever is present in about a third of patients on the first day after stroke onset and is associated with poor outcome. However, the temporal profile of this association is not well established. We aimed to assess the relationship between body temperature on admission as well as the change in body temperature from admission to 24 h thereafter and functional outcome and death. We analyzed data of 1,332 patients admitted within 12 h of stroke onset. The relation between body temperature on admission or the change in body temperature from admission to 24 h thereafter (adjusted for body temperature on admission) on the one hand and unfavorable outcome (death, or a modified Rankin Scale score >2) at 3 months on the other were expressed as odds ratio per 1.0°C increase in body temperature. Adjustments for potential confounders were made with a multiple logistic regression model. No relation was found between admission body temperature and poor outcome (aOR 1.06; 95% CI 0.85–1.32) and death (aOR 1.23; 95% CI 0.95–1.60). In contrast, increased body temperature in the first 24 h after stroke onset was associated with poor outcome (aOR 1.30; 95% CI 1.05–1.63) and death (aOR 1.51; 95% CI 1.15–1.98). An early rise in body temperature rather than high body temperature on admission is a risk factor for unfavorable outcome in patients with acute stroke.
- 30 September 2010
- Published by Springer Nature in Journal of Neurology
- Vol. 258 (2) , 302-307
Open AccessAn early rise in body temperature is related to unfavorable outcome after stroke: data from the PAIS study
Subfebrile temperature or fever is present in about a third of patients on the first day after stroke onset and is associated with poor outcome. However, the temporal profile of this association is not well established. We aimed to assess the relationship between body temperature on admission as well as the change in body temperature from admission to 24 h thereafter and functional outcome and death. We analyzed data of 1,332 patients admitted within 12 h of stroke onset. The relation between body temperature on admission or the change in body temperature from admission to 24 h thereafter (adjusted for body temperature on admission) on the one hand and unfavorable outcome (death, or a modified Rankin Scale score >2) at 3 months on the other were expressed as odds ratio per 1.0°C increase in body temperature. Adjustments for potential confounders were made with a multiple logistic regression model. No relation was found between admission body temperature and poor outcome (aOR 1.06; 95% CI 0.85–1.32) and death (aOR 1.23; 95% CI 0.95–1.60). In contrast, increased body temperature in the first 24 h after stroke onset was associated with poor outcome (aOR 1.30; 95% CI 1.05–1.63) and death (aOR 1.51; 95% CI 1.15–1.98). An early rise in body temperature rather than high body temperature on admission is a risk factor for unfavorable outcome in patients with acute stroke.
- Open Access
- 17 July 2009
- Published by Springer Nature in Journal of Neurology
- Vol. 256 (12) , 2003-2008
C-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death
Acute ischemic stroke may trigger an inflammatory response that leads to increased levels of C-reactive protein (CRP). High levels of CRP may be associated with poor outcome because they reflect either an inflammatory reaction or tissue damage. We evaluated the prognostic value of CRP within 12 h of onset of ischemic stroke. Levels of CRP were routinely obtained within 12 h of symptom onset in 561 patients with ischemic stroke. CRP values were dichotomized as 2) or death at 3 months. A multiple logistic regression model was applied to adjust for age, sex, NIHSS score, current cigarette smoking, diabetes mellitus, hypertension, statin use, and stroke subtype. After adjustment for potential confounders, patients with CRP levels ≥7 mg/L had a significantly increased risk of poor outcome (adjusted OR 1.6, 95% CI 1.1–2.4) or death (adjusted OR 1.7, 95% CI 1.0–2.9) at 3 months. In addition, the risk of poor outcome or death at 3 months increased with higher levels of CRP. CRP within 12 h of ischemic stroke is an independent prognostic factor of poor outcome at 3 months.
- 17 July 2009
- Published by Springer Nature in Journal of Neurology
- Vol. 256 (12) , 2003-2008
Open AccessC-reactive protein in the very early phase of acute ischemic stroke: association with poor outcome and death
Acute ischemic stroke may trigger an inflammatory response that leads to increased levels of C-reactive protein (CRP). High levels of CRP may be associated with poor outcome because they reflect either an inflammatory reaction or tissue damage. We evaluated the prognostic value of CRP within 12 h of onset of ischemic stroke. Levels of CRP were routinely obtained within 12 h of symptom onset in 561 patients with ischemic stroke. CRP values were dichotomized as 2) or death at 3 months. A multiple logistic regression model was applied to adjust for age, sex, NIHSS score, current cigarette smoking, diabetes mellitus, hypertension, statin use, and stroke subtype. After adjustment for potential confounders, patients with CRP levels ≥7 mg/L had a significantly increased risk of poor outcome (adjusted OR 1.6, 95% CI 1.1–2.4) or death (adjusted OR 1.7, 95% CI 1.0–2.9) at 3 months. In addition, the risk of poor outcome or death at 3 months increased with higher levels of CRP. CRP within 12 h of ischemic stroke is an independent prognostic factor of poor outcome at 3 months.
- 1 July 2009
- Published by Wolters Kluwer Health in Stroke
- Vol. 40 (7) , 481-482
Temperature-Lowering Therapy for Acute Stroke
- 1 July 2009
- Published by Wolters Kluwer Health in Stroke
- Vol. 40 (7) , 481-482
Temperature-Lowering Therapy for Acute Stroke
- 1 May 2009
- Published by Elsevier in The Lancet Neurology
- Vol. 8 (5) , 434-440
The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial
- 1 May 2009
- Published by Elsevier in The Lancet Neurology
- Vol. 8 (5) , 434-440
The Paracetamol (Acetaminophen) In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III trial
- 21 January 2009
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2010 (1) , CD001247
Cooling therapy for acute stroke
Increased body temperatures are common in patients with acute stroke and are associated with poor outcome. In animal models of focal cerebral ischaemia, temperature-lowering therapy reduces infarct volume. In patients with acute stroke, lowering temperature may therefore improve outcome. This is an update of a Cochrane review first published in 1999. To assess the effects of pharmacological and physical strategies to reduce body or brain temperature in patients with acute stroke. We searched the Cochrane Stroke Group trials register (last searched December 2007). In addition, we searched MEDLINE and EMBASE (January 1998 to December 2007). We scanned references and contacted authors of included trials. For the previous version of this review, the authors contacted pharmaceutical companies and manufactures of cooling equipment in this field. We considered all completed randomised or non-randomised controlled clinical trials, published or unpublished, where pharmacological or physical strategies or both to reduce temperature were applied in patients with acute ischaemic stroke or intracerebral haemorrhage. Outcome measures were death or dependency (modified Rankin Scale score ≥ 3) at the end of follow up, and adverse effects. Two review authors independently applied the inclusion criteria, assessed trial quality, and extracted and cross-checked the data. We included five pharmacological temperature reduction trials and three physical cooling trials involving a total of 423 participants. We found no statistically significant effect of pharmacological or physical temperature-lowering therapy in reducing the risk of death or dependency (odds ratio (OR) 0.9, 95% confidence interval (CI) 0.6 to 1.4) or death (OR 0.9, 95% CI 0.5 to 1.5). Both interventions were associated with a non-significant increase in the occurrence of infections. There is currently no evidence from randomised trials to support routine use of physical or pharmacological strategies to reduce temperature in patients with acute stroke. Large randomised clinical trials are needed to study the effect of such strategies. Traitement de refroidissement dans l'accident vasculaire cérébral (AVC) aigu Il est fréquent que les patients victimes d'un AVC aigu aient une température corporelle élevée, ce qui est associé à de mauvais résultats. Dans les modèles animaux d'ischémie cérébrale focale, le traitement de diminution de la température réduit le volume de l'infarctus. Chez les patients victimes d'un AVC aigu, une baisse de la température pourrait donc améliorer les résultats. Cette revue est une mise à jour d'une revue Cochrane publiée pour la première fois en 1999. Évaluer les effets de stratégies pharmacologiques et physiques visant à faire baisser la température corporelle ou cérébrale chez des patients victimes d'AVC aigu. Nous avons consulté le registre d'essais du groupe Cochrane sur les accidents vasculaires cérébraux (dernière recherche décembre 2007). De plus, nous avons consulté MEDLINE et EMBASE (de janvier 1998 à décembre 2007). Nous avons examiné les références et contacté les auteurs des essais inclus. Pour la version précédente de cette revue, les auteurs ont contacté des entreprises pharmaceutiques et des fabricants d'équipements de refroidissement dans ce domaine. Nous avons pris en compte tous les essais cliniques contrôlés randomisés ou non randomisés achevés, publiés ou non publiés, dans lesquels des stratégies pharmacologiques ou physiques, ou les deux, visant à faire baisser la température étaient appliquées à des patients victimes d'AVC ischémique aigu ou d'hémorragie intracérébrale. Les critères de jugement étaient la mortalité ou la dépendance (score de l'échelle Rankin modifié ≥ 3) à la fin du suivi et les effets secondaires. Deux auteurs de la revue ont appliqué indépendamment les critères d'admissibilité, évalué la qualité des essais et extrait et contre-vérifié les données. Nous avons inclus cinq essais sur la diminution pharmacologique de la température et trois essais sur le refroidissement physique avec au total 423 participants. Nous n'avons trouvé aucun effet statistiquement significatif des traitements pharmacologiques ou physiques de diminution de la température sur la réduction du risque de décès ou dépendance (rapport des cotes (RC) 0,9, intervalle de confiance (IC) à 95 % de 0,6 à 1,4) ou de décès (RC 0,9, IC à 95 % de 0,5 à 1,5). Les deux interventions étaient associées à une augmentation non significative de l'occurrence d'infections. Il n'existe actuellement aucune preuve issue d'essais randomisés favorable à l'utilisation habituelle de stratégies physiques ou pharmacologiques pour réduire la température chez les patients victimes d'AVC aigu. De vastes essais cliniques randomisés sont nécessaires pour étudier l'effet de ces stratégies. 急性脳卒中に対する冷却療法 体温上昇は急性脳卒中の患者で一般的にみられ、不良なアウトカムに関係している。局所性脳虚血の動物モデルでは体温低下療法が梗塞量を減少させることが示されている。従って、急性脳卒中の患者の体温低下によってアウトカムが改善するかもしれない。本レビューは、1999年に最初に発表されたコクラン・レビューの改訂版である。 急性脳卒中の患者の体温または脳温を低下させるための薬理的および物理的戦略の効果を評価する。 Cochrane Stroke Group trials register(最終検索2007年12月)を検索した。これに加えて、MEDLINEおよびEMBASE(1998年1月~2007年12月)を検索した。参照文献を精査し、選択した試験の著者に問い合わせた。本レビューの以前の版では、レビューアは製薬企業および本分野の冷却装置の製造業者に問い合わせた。...
- 21 January 2009
- Published by Wiley in Cochrane Database of Systematic Reviews
- Vol. 2010 (1) , CD001247
Cooling therapy for acute stroke
Increased body temperatures are common in patients with acute stroke and are associated with poor outcome. In animal models of focal cerebral ischaemia, temperature-lowering therapy reduces infarct volume. In patients with acute stroke, lowering temperature may therefore improve outcome. This is an update of a Cochrane review first published in 1999. To assess the effects of pharmacological and physical strategies to reduce body or brain temperature in patients with acute stroke. We searched the Cochrane Stroke Group trials register (last searched December 2007). In addition, we searched MEDLINE and EMBASE (January 1998 to December 2007). We scanned references and contacted authors of included trials. For the previous version of this review, the authors contacted pharmaceutical companies and manufactures of cooling equipment in this field. We considered all completed randomised or non-randomised controlled clinical trials, published or unpublished, where pharmacological or physical strategies or both to reduce temperature were applied in patients with acute ischaemic stroke or intracerebral haemorrhage. Outcome measures were death or dependency (modified Rankin Scale score ≥ 3) at the end of follow up, and adverse effects. Two review authors independently applied the inclusion criteria, assessed trial quality, and extracted and cross-checked the data. We included five pharmacological temperature reduction trials and three physical cooling trials involving a total of 423 participants. We found no statistically significant effect of pharmacological or physical temperature-lowering therapy in reducing the risk of death or dependency (odds ratio (OR) 0.9, 95% confidence interval (CI) 0.6 to 1.4) or death (OR 0.9, 95% CI 0.5 to 1.5). Both interventions were associated with a non-significant increase in the occurrence of infections. There is currently no evidence from randomised trials to support routine use of physical or pharmacological strategies to reduce temperature in patients with acute stroke. Large randomised clinical trials are needed to study the effect of such strategies. Traitement de refroidissement dans l'accident vasculaire cérébral (AVC) aigu Il est fréquent que les patients victimes d'un AVC aigu aient une température corporelle élevée, ce qui est associé à de mauvais résultats. Dans les modèles animaux d'ischémie cérébrale focale, le traitement de diminution de la température réduit le volume de l'infarctus. Chez les patients victimes d'un AVC aigu, une baisse de la température pourrait donc améliorer les résultats. Cette revue est une mise à jour d'une revue Cochrane publiée pour la première fois en 1999. Évaluer les effets de stratégies pharmacologiques et physiques visant à faire baisser la température corporelle ou cérébrale chez des patients victimes d'AVC aigu. Nous avons consulté le registre d'essais du groupe Cochrane sur les accidents vasculaires cérébraux (dernière recherche décembre 2007). De plus, nous avons consulté MEDLINE et EMBASE (de janvier 1998 à décembre 2007). Nous avons examiné les références et contacté les auteurs des essais inclus. Pour la version précédente de cette revue, les auteurs ont contacté des entreprises pharmaceutiques et des fabricants d'équipements de refroidissement dans ce domaine. Nous avons pris en compte tous les essais cliniques contrôlés randomisés ou non randomisés achevés, publiés ou non publiés, dans lesquels des stratégies pharmacologiques ou physiques, ou les deux, visant à faire baisser la température étaient appliquées à des patients victimes d'AVC ischémique aigu ou d'hémorragie intracérébrale. Les critères de jugement étaient la mortalité ou la dépendance (score de l'échelle Rankin modifié ≥ 3) à la fin du suivi et les effets secondaires. Deux auteurs de la revue ont appliqué indépendamment les critères d'admissibilité, évalué la qualité des essais et extrait et contre-vérifié les données. Nous avons inclus cinq essais sur la diminution pharmacologique de la température et trois essais sur le refroidissement physique avec au total 423 participants. Nous n'avons trouvé aucun effet statistiquement significatif des traitements pharmacologiques ou physiques de diminution de la température sur la réduction du risque de décès ou dépendance (rapport des cotes (RC) 0,9, intervalle de confiance (IC) à 95 % de 0,6 à 1,4) ou de décès (RC 0,9, IC à 95 % de 0,5 à 1,5). Les deux interventions étaient associées à une augmentation non significative de l'occurrence d'infections. Il n'existe actuellement aucune preuve issue d'essais randomisés favorable à l'utilisation habituelle de stratégies physiques ou pharmacologiques pour réduire la température chez les patients victimes d'AVC aigu. De vastes essais cliniques randomisés sont nécessaires pour étudier l'effet de ces stratégies. 急性脳卒中に対する冷却療法 体温上昇は急性脳卒中の患者で一般的にみられ、不良なアウトカムに関係している。局所性脳虚血の動物モデルでは体温低下療法が梗塞量を減少させることが示されている。従って、急性脳卒中の患者の体温低下によってアウトカムが改善するかもしれない。本レビューは、1999年に最初に発表されたコクラン・レビューの改訂版である。 急性脳卒中の患者の体温または脳温を低下させるための薬理的および物理的戦略の効果を評価する。 Cochrane Stroke Group trials register(最終検索2007年12月)を検索した。これに加えて、MEDLINEおよびEMBASE(1998年1月~2007年12月)を検索した。参照文献を精査し、選択した試験の著者に問い合わせた。本レビューの以前の版では、レビューアは製薬企業および本分野の冷却装置の製造業者に問い合わせた。...
- Open Access
- 4 November 2008
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 8 (1) , 29
Erratum to: PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial. [ISCRTN74418480]
Background: The Paracetamol (Acetaminophen) In Stroke (PAIS) study is a phase III multicenter, double blind, randomized, placebo-controlled clinical trial of high-dose acetaminophen in patients with acute stroke. The trial compares treatment with a daily dose of 6 g acetaminophen, started within 12 hours after the onset of symptoms, with matched placebo. The purpose of this study is to assess whether treatment with acetaminophen for 3 days will result in improved functional outcome through a modest reduction in body temperature and prevention of fever. The previously planned statistical analysis based on a dichotomization of the scores on the modified Rankin Scale (mRS) may not make the most efficient use of the available baseline information. Therefore, the planned primary analysis of the PAIS study has been changed from fixed dichotomization of the mRS to a sliding dichotomy analysis. Methods: Instead of taking a single definition of good outcome for all patients, the definition is tailored to each individual patient's baseline prognosis on entry into the trial. Conclusion: The protocol change was initiated because of both advances in statistical approaches and to increase the efficiency of the trial by improving statistical power. Trial Registration: Current Controlled Trials [ISCRTN74418480]
- 4 November 2008
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 8 (1) , 29
Open AccessErratum to: PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial. [ISCRTN74418480]
Background: The Paracetamol (Acetaminophen) In Stroke (PAIS) study is a phase III multicenter, double blind, randomized, placebo-controlled clinical trial of high-dose acetaminophen in patients with acute stroke. The trial compares treatment with a daily dose of 6 g acetaminophen, started within 12 hours after the onset of symptoms, with matched placebo. The purpose of this study is to assess whether treatment with acetaminophen for 3 days will result in improved functional outcome through a modest reduction in body temperature and prevention of fever. The previously planned statistical analysis based on a dichotomization of the scores on the modified Rankin Scale (mRS) may not make the most efficient use of the available baseline information. Therefore, the planned primary analysis of the PAIS study has been changed from fixed dichotomization of the mRS to a sliding dichotomy analysis. Methods: Instead of taking a single definition of good outcome for all patients, the definition is tailored to each individual patient's baseline prognosis on entry into the trial. Conclusion: The protocol change was initiated because of both advances in statistical approaches and to increase the efficiency of the trial by improving statistical power. Trial Registration: Current Controlled Trials [ISCRTN74418480]